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therapeutic strategy for colon cancer. 3-Deazaneplanocin A (DZNep), as an EZH2 inhibitor, can suppress
cancer cell growth. However, the anti-cancer role of DZNep in colon cancer cells has been rarely studied.
In this study, we demonstrate that DZNep can inhibit the growth and survival of colon cancer HCT116
cells by inducing cellular senescence and apoptosis. The study provides a novel view of anti-cancer
mechanisms of DZNep in human colon cancer cells.
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Effect of DZNep on HCT116 cells 1891. Introduction
Colon cancer has become the third leading cause of tumor-related
deaths in the world1, and its incidence is rapidly rising in Chinese
cities along with economic development2. Colon cancer normally
develops through a multistep process that results from the
progressive accumulation of mutations and epigenetic alterations
in tumor suppressor genes and oncogenes, which include both
DNA hypermethylation and chromatin modiﬁcations such as
histone methylation and deacetylation3. Recently, the study of
epigenetic gene silencing by histone methylation has gained
attention in the development of colon cancer.
Enhancer of zeste homolog-2 (EZH2), a histone methyltransfer-
ase, is the catalytic subunit of polycom repressive complex 2
(PRC2) that methylates H3K27me3 and results in epigenetic
control of cancer genes expression4,5. Up-regulation of EZH2
has been found in many malignant human tumors, including
colorectal carcinomas, and a high level of EZH2 positively
correlates with colon cancer metastasis6. Thus, EZH2 has become
a promising therapeutic target for colon cancer treatment.
3-Deazaneplanocin A (DZNep), a S-adenosyl-L-homocysteine
(AdoHcy) hydrolase, has been shown to be capable of reducing the
expression of EZH27. Although DZNep was shown to be able to
inhibit the proliferation as well as the metastasis and invasion of a
variety of cancer cells, such as lung cancer and breast cancer8,9,
little is known with regard to the effects and mechanisms of
DZNep on colon cancer cells.
Cellular senescence has become a vital anti-cancer mechanism due
to irreversible cell cycle arrest and permanent inhibition of cancer cell
growth10,11. Inhibition of EZH2 was shown to promote senescence
and apoptosis induced by doxorubicin in gastric cancer cells harboring
mutant p5312. However, direct evidence linking EZH2 inhibition by
pharmacological intervention with cell senescence in colon cancer
cells is still lacking. Here, we investigated the role of DZNep in colon
cancer HCT116 cells, and found that both senescence and apoptosis
contribute to the anti-cancer effects of the compound.
2. Materials and methods
2.1. Reagents and materials
3-Deazaneplanocin A hydrochloride (DZNep) and propidium
iodide (PI) were purchased from Sigma-Aldrich. MTT was
purchased from Amresco (Solon, OH). AnnexinV-PI was pur-
chased from Beijing 4A Biotech Co., Ltd. Senescence associated
β-galactosidase (SA-β-gal) staining kit was purchased from
Beyotime Institute of Biotechnology. Antibody for β-actin and
EED were purchased from Sigma. EZH2, SUZ12 and other
antibodies were purchased from Cell Signaling Technology.
2.2. Cell culture
HCT116 was cultured and maintained in DMEM (Hyclone,
Logan, UT) supplemented with 10% (v/v) fetal bovine serum
(FBS, Life Technology), 100 U/mL penicillin G (Amresco) and
100 μg/mL streptomycin (Amresco). The cells were cultured in a
humidiﬁed atmosphere of 5% CO2 at 37 1C.
2.3. Cellular viability measurement
Cellular viability was performed with the MTT assay as described
previously7. The cells were seeded at 5000 cells/well in 96-wellplates for 24 h and treated with different concentrations of DZNep
for another 48 h, then incubated in MTT solution for 4 h at
37 1C. MTT solution was then carefully removed and replaced by
100 μL DMSO to dissolve formazan crystals. Absorbance was
measured using a microplate reader (Bio-Rad) at a wavelength of
570 nm. The control group was set as 100%, and IC50 values were
calculated and plotted with Graphpad Prism 5. This experiment
was conducted in triplicates three times.
2.4. Colony formation and cell growth assay
Cellular sensitivity to DZNep was determined using a previously
described protocol13. In brief, HCT116 cells were seeded at a
density of 500 cells/well into 35 mm dishes and treated as
indicated. After incubation for 2 weeks, the colonies obtained
were ﬁxed in 3% paraformaldehyde for 15 min and then washed
with PBS followed by staining with hematoxylin. HCT116 cells
were seeded into 96-well plate with 104 cells/well in triplicate for
cell counting at indicated time points with a Countess Cell Counter
(Life Technology).
2.5. SA-β-gal staining
SA-β-gal activity staining was performed using SA-β-gal staining
kit (Beyotime Institute of Biotechnology, Haimen, China) accord-
ing to the manufacturer's protocol. The cells were seeded at
5 104 cells/well in 6-well plates, and treated with DZNep at
5 μmol/L for the indicated time. The cells were washed three times
with PBS and ﬁxed with 4% paraformaldehyde for 15 min at room
temperature. The cells then were incubated overnight at 37 1C with
the working solution containing 0.05 mg/mL X-gal using SA-β-gal
staining kit (Beyotime Biotechnology).
2.6. Apoptosis assay
Apoptosis assay was performed using the Annexin V Alexa Fluor
488/PI apoptosis detection Kit (Beijing 4A Biotech Co., Ltd.)
according to the manufacturer's instructions. Brieﬂy, after treated
as indicated, both ﬂoating and non-ﬂoating cells were collected
after trypsinization, and then washed twice in PBS, followed by re-
suspension in Annexin-V binding buffer at a concentration of
106 cells/mL. An aliquot of 100 μL of this suspension was stained
with 5 μL of Annexin-V Alexa Fluor 488 and 5 μL PI, and
incubated at room temperature in the darkness for 15 min.
Subsequently, the cells were added to 400 μL PBS and subjected
to FACS analysis in a FACS Calibur (Becton Dickinson instruc-
tion, BD Bioscience).
2.7. Flow cytometry and cell cycle analysis
The cells were harvested and ﬁxed in 70% ethanol at 20 1C
overnight. The ﬁxed cells were stained with PI for 1 h after
treatment with RNase at 37 1C for 30 min in the darkness. The
stained cells were analyzed for DNA content by FACS. The cell
cycle fractions were quantiﬁed using the Cell Quest Acquisition
and Analysis (BD Bioscience).
2.8. Immunoblotting analysis
Immunoblotting analysis was determined using a previously
described protocol14. The cells were washed with icy PBS and
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(CST) plus 1 mmol/L PMSF. Protein concentration was deter-
mined by Bradford assay. Equal amounts of protein were
separated by 10%–15% sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred onto PVDF membranes
(Whatman). The membranes were blocked with 5% nonfat milk
PBS-T buffer at room temperature for 1 h, and then incubated
with primary antibodies at 4 1C overnight. The membranes were
then incubated for 1 h with an appropriate horseradish peroxidase
linked secondary antibody, and electrochemiluminescence was
performed with a ChemiImager 5500 imaging system (Alpha
Innotech Corporation).
2.9. Statistical analysis
SPSS 19.0 statistical software was used for statistical analysis.
Values are shown as the mean7SD. Statistical analysis was
carried out using Student's t-test. Differences between groups
were identiﬁed as statistically signiﬁcant at Po0.05.3. Results
3.1. DZNep inhibits the growth of HCT116 cells
MTT assay was used to screen the effective concentration of
DZNep on human colon cancer HCT116 cells. The cells were
treated with DZNep for 48 h at the concentration of 0, 0.08, 0.4, 2,
10 and 50 μmol/L. DZNep induced potent growth inhibition in aFigure 1 DZNep inhibited the proliferation of HCT116 cells. (A) Effect
The cells were treated in 96-well plates for 48 h with DZNep at the indicat
were seeded into 24-well plates with 1 104 cells/well for 24 h, and then tr
(*Po0.05, **Po0.01 vs. control, n¼3). (C) Colony formation upon DZNe
dish, and then treated with 5 μmol/L DZNep for 2 weeks. The percentage
control, n¼3).dose-dependent manner (Fig. 1A). We used 5 μmol/L DZNep at
IC50 range for further study, and found that DZNep signiﬁcantly
inhibited the cellular proliferation in a time-dependent way, as
indicated by the growth curve (Fig. 1B). Longer treatment of
DZNep also displayed signiﬁcant growth inhibition with colony
formation assay (Fig. 1C).
3.2. DZNep induces G1 cell cycle arrest in HCT116 cells
We next used ﬂow cytometry to determine whether the suppres-
sion of proliferation was due to cell cycle arrest in HCT116 cells.
After treatment with DZNep for 24 h, the cellular ratio in G1 phase
increased from 41.09% to 55.14%, and the ratio in S phase
decreased from 38.24% to 30.73% (Fig. 2). Higher ratio of G1
phase was seen upon DZNep treatment for 48 h and 72 h (Fig. 2).
This suggests that DZNep induces G1 cell cycle arrest in
HCT116 cells.
3.3. DZNep induces cellular senescence in HCT116 cells
Inhibition of EZH2 is suggested to induce cancer cell senes-
cence15. We thus checked whether DZNep was able to induce cell
senescence in HCT116 cells as well. After the cells were treated
with DZNep for 48 h, 72 h and 96 h, we used SA-β-gal staining to
observe the senescence-like phenotype, and found that many cells
became positively stained upon DZNep exposure (Fig. 3A). This
suggests that DZNep induces cellular senescence simultaneously
under these conditions. Similarly, senescence was observed upon
EZH2 siRNA treatment for 72 h (Fig. 3B).of DZNep on the proliferation of HCT116 determined by MTT assay.
ed concentration. (B) Effect of DZNep on the growth curve. The cells
eated with or without 5 μmol/L DZNep and counted at indicated points
p treatment. The cells were seeded in 35 mm dishes with 500 cells per
of the colonies was normalized relative to the control (***Po0.001 vs.
Figure 3 Inhibition the expression of EZH2 induced cellular senescence in HCT116 cells. The cells were treated with 5 μmol/L DZNep (A) or
with siRNA (B) for the indicated time, and senescence was analyzed with SA-β-gal staining and photographed (40). Scale bar: 50 μm.
Figure 2 DZNep induced cell cycle arrest in HCT116 cells. The cells were treated with 5 μmol/L DZNep for the indicated time before being
subjected to PI staining and FACS analysis as described in Section 2.
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expression in HCT116 cells
We further investigated the possible molecular mechanisms
involved. The expression levels of PRC2 proteins (EZH2, EED
and SUZ12) were conﬁrmed to be suppressed after treatment with
DZNep for 48 h, 72 h, 96 h and 120 h, as shown by immunoblot
analysis in HCT116 cells (Fig. 4). Cell cycle and senescence
regulatory proteins were investigated to clarify the underlying
mechanism16, and a signiﬁcant increase of p21 and decrease of
p-RB protein expression were found upon exposure to the agent.
In addition, we examined the expression of p27 and p-CDC2,
which are cell cycle regulators as well17, and found that DZNepincreased p27 and decreased p-CDC2 expression in a time-
dependent manner (Fig. 4).3.5. DZNep induces apoptosis in HCT116 cells
We also asked whether apoptosis is involved. Flow cytometry
analysis using Annexin V/PI demonstrated that the apoptotic
fraction of HCT116 cells was increased in a time-dependent
manner following treatment with DZNep (Fig. 5A). We also
analyzed PARP cleavage, a well-known molecular event indicat-
ing apoptosis induction18, and found a signiﬁcant increase of
PARP cleavage upon treatment with 5 μmol/L DZNep for 24 h,
Mingquan Sha et al.19248 h and 72 h (Fig. 5B). This indicates that DZNep induces
apoptosis as well.4. Discussion
EZH2-targeted therapy has become an effective strategy for cancer
treatment. For example, blocking the expression of EZH2 by
siRNA leads to G1/S cell cycle arrest and growth inhibition in
colon cancer19. Moreover, decreased EZH2 expression is found to
be able to increase the sensitivity to TRAIL-mediated apoptosis inFigure 4 Relative protein expression levels affected by DZNep in
HCT116 cells. The cells were treated with 5 μmol/L DZNep for 72 h
before being subjected to immunoblot assay as described in Section 2.
Figure 5 DZNep induced apoptosis in HCT116 cells. (A) Apoptosis indu
seeded in 6-well plates and treated with 5 μmol/L DZNep for the indicated
of early apoptosis cells (lower right quadrant) and late apoptosis cells (u
cleavage analysis was performed in HCT116 cells following treatment withhuman colon cancer HT29 cells20. In the present work, we provide
ﬁrst evidence to show that inhibition of EZH2 by DZNep can
directly induce cell senescence, along with apoptosis, in human
colon cancer HCT116 cells.
Cellular senescence of HCT116 cells induced by DZNep is
demonstrated by G1 phase arrest and an increased number of cells
with positive SA-β-gal staining, which is one of most commonly
used senescence markers. We found that the cell cycle arrest caused
by DZNep can be addressed by the increase of p21 expression and
decrease of p-RB expression. Moreover, p27 and p-CDC2, which
blocks cell cycle progression at the G1 transition and promotes G1
and G2/M transition17,21, respectively, are found to be separately
up-regulated and down-regulated as well. In line with our data,
silencing of EZH2 is reported to be linked to the increase of p27
expression in pancreatic cancer cells and HCT116 cells11,22. We
also checked the expression of p16, another molecular marker
associated with senescence and cell cycle, but did not ﬁnd any
signiﬁcant change in the protein level (data not shown).
In our work, we also found that DZNep can dose- and time-
dependently induce colon cancer cell apoptosis, as conﬁrmed by
FACS analysis and PARP cleavage (Fig. 5). Accordingly, DZNep-
induced apoptosis has been described in osteosarcoma U2OS and
breast cancer MCF7 cells23,24. More importantly, DZNep at a
similar dose range was found to induce apoptosis in human colon
cancer stem cells as well25. Therefore, combined mechanisms are
involved in the anti-cancer effects of DZNep on colon cancer. A
study by Wu et al.23 has shown that DZNep induces apoptosis and
G1 cell cycle arrest in response to DNA damage in both p53-
proﬁcient and p53-deleted HCT116 cells, resulting in induction of
FBXO32, a decrease of p21 and an increase of PARP cleavage.
This seems to be inconsistent with our data which suggests an
increase of p21 upon DZNep exposure. The discrepancy in p21
regulation may rely on the different stresses imposed on the cells.
Taken together, our results demonstrate that DZNep inhibits the
growth and survival of colon cancer HCT116 cells by inducingced by DZNep was detected by AnnexinV/PI staining. The cells were
time, and then subjected to FACS analysis to determine the percentage
pper right quadrant) (**Po0.01, ***Po0.001 vs. control). (B) PARP
DZNep (5 μmol/L) as indicated. β-actin was used as loading control.
Effect of DZNep on HCT116 cells 193cellular senescence and apoptosis. The study also provides ﬁrst
evidence showing the direct correlation between inhibition of
EZH2 and cellular senescence in colon cancer cells.
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